Q2 FY2026 EarningsQ2 FY26 significantly beat consensus across all key financial metrics, driven by a substantial $55.7M revenue recognition from a European licensing deal. Revenue of $218.3M outperformed the $183.3M expectation, while GAAP EPS of $0.30 crushed the $0.1189 mean estimate. Management raised FY26 total revenue guidance to $690M–$715M (vs. $635M–$660M previously) and improved OpEx guidance, signaling enhanced profitability and commercial momentum for ORLADEYO.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: BioCryst Pharma(BCRX) the Revenue is 218.25 M (+33.61%), Beat estimate;the EBIT is 98.47 M (+230.6%), Beat estimate;the EPS is 0.3 (+1400%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.22B33.61%
0.18B12.23%
+0.03B21.38%
EBITExceed expectations
0.10B230.57%
0.05B52.06%
+0.05B178.51%
EPSExceed expectations
0.31400.00%
0.1189494.70%
+0.1811905.30%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf